Patient Guide: A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 65 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT03958877
Status: ACTIVE_NOT_RECRUITING
Condition: Multiple Sclerosis, Relapsing-Remitting
Phase: PHASE3

Where You Can Participate

This study is available at 65 locations across the country.

Top locations include:
  • • La Jolla, California
  • • Chapel Hill, North Carolina
  • • Norfolk, Virginia
  • • And 62 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis - Join Clinical Trial NCTNCT03958877

How to Join This Clinical Trial - NCTNCT03958877

Learn how to participate in this PHASE3 trial studying an investigational therapy for Multiple Sclerosis, Relapsing-Remitting. Current status: ACTIVE_NOT_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Multiple Sclerosis, Relapsing-Remitting. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Multiple Sclerosis, Relapsing-Remitting
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
ACTIVE_NOT_RECRUITING
Study Identifier
NCTNCT03958877 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 65 locations. Find a study site near you:

Clinical Research Site

La Jolla, California 92024 - United States

Status: Contact for availability

Clinical Research Site

Chapel Hill, North Carolina 27514 - United States

Status: Contact for availability

Clinical Research Site

Norfolk, Virginia 23502 - United States

Status: Contact for availability

Clinical Research Site

Ciudad Autonoma Buenos Aires, Buenos Aires 1199 - Argentina

Status: Contact for availability

Clinical Research Site

Parkville, Victoria 3052 - Australia

Status: Contact for availability

Clinical Research Site

Ghent, East Flanders 9000 - Belgium

Status: Contact for availability

Clinical Research Site

Liège, Wallonia 4000 - Belgium

Status: Contact for availability

Clinical Research Site

Sofia, 1113 - Bulgaria

Status: Contact for availability

Clinical Research Site

Split, Dalmatia 21000 - Croatia

Status: Contact for availability

Clinical Research Site

Zagreb, 10000 - Croatia

Status: Contact for availability

And 55 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Multiple Sclerosis, Relapsing-Remitting:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships